This study investigated the humoral immunization of Astragalus polysaccharide （APS） against HgN2 avian influenza virus （H9N2 AIV） infection in chickens. The effects of APS treatment on H9N2 infection was evaluated...This study investigated the humoral immunization of Astragalus polysaccharide （APS） against HgN2 avian influenza virus （H9N2 AIV） infection in chickens. The effects of APS treatment on H9N2 infection was evaluated by an Mqq- [3（4, 5-dimethylthiazol-2-yl）-2, 3-diphenyl tetrazolium bromide] assay and analysis of MFIC and cytokine mRNA expression. The effect on lymphocyte and serum antibody titers in vivo was also investigated. IL-4, IL-6, IL-10, LITAF, IL-12 and antibody titers to H9N2 AIV wet enhanced in the first week after APS treatment. The results indicated that APS treatment reduces H9N2 AIV replication and promotes early humoral immune responses in young chickens.This study investigated the humoral immunization of Astragalus polysaccharide （APS） against HgN2 avian influenza virus （H9N2 AIV） infection in chickens. The effects of APS treatment on HgN2 infection was evaluated by an M]q- [3（4, 5-dimethylthiazol-2-yl）-2, 3-diphenyl tetrazolium bromide] assay and analysis of MHC and cytokine mRNA expression. The effect on lymphocyte and serum antibody titers in vivo was also investigated. IL-4, IL-6, IL-10, LITAF, IL-12 and antibody titers to PIgN2 AIV were enhanced in the first week after APS treatment. The results indicated that APS treatment reduces HgN2 AIV replication and promotes early humoral immune responses in young chickens.展开更多
Objective： To evaluate the potential adjuvant effect of Agrocybe aegerita lectin （AAL）, which was isolatedfrom mushroom, against a virulent H9N2 strain in vivo and in vitro. Methods： In trial 1, 50 BALB/c male mi...Objective： To evaluate the potential adjuvant effect of Agrocybe aegerita lectin （AAL）, which was isolatedfrom mushroom, against a virulent H9N2 strain in vivo and in vitro. Methods： In trial 1, 50 BALB/c male mice （8 weeksold） were divided into five groups （n=10 each group） which received a subcutaneous injection of inactivated HgN2（control）, inactivated HgN2＋0.2% （w/w） alum, inactivated HgN2＋0.5 mg recombinant AAL/kg body weight （BW）, inac-tivated HgN2＋1.0 mg AAl_/kg BW, and inactivated H9N2＋2.5 mg AAL/kg BW, respectively, four times at 7-d intervals. Intrial 2, 30 BALB/c male mice （8 weeks old） were divided into three groups （n=10 each group） which received a sub-cutaneous injection of inactivated HgN2 （control）, inactivated HmN2＋2.5 mg recombinant wild-type AAL （AAL-wt）/kg BWand inactivated H9N2＋2.5 mg carbohydrate recognition domain （CRD） mutant AAL （AAL-mutR63H）/kg BW,respectively, four times at 7-d intervals. Seven days after the final immunization, serum samples were collectedfrom each group for analysis. Hemagglutination assay, immunogold electron microscope, lectin blotting, and co-immunoprecipitation were used to study the interaction between hAL and HgN2 in vitro. Results： IgG, IgG1, and IgG2aantibody levels were significantly increased in the sera of mice co-immunized with inactivated HgN2 and AAL whencompared to mice immunized with inactivated H^N2 alone. No significant increase of the IgG antibody level was de-tected in the sera of the mice co-immunized with inactivated HgN2 and AAL-mutR63H. Moreover, AAL-wt, but notmutant AAL-mutR63H, adhered to the surface of H9N2 virus. The interaction between AAL and the H9N2 virus wasfurther demonstrated to be associated with the CRD of AAL binding to the surface glycosylated proteins, hemagglutininand neuraminidase. Conclusions： Our findings indicated that AAL could be a safe and effective adjuvant capable ofboosting humoral immunity against HgN2 viruses in mice through its interaction with the viral surface glycosylatedproteins, hemagglutinin and neuraminidase.展开更多
基金supported by funds provided by South China Agricultural University and Guangzhou work team project(No 2011A020102009)
文摘This study investigated the humoral immunization of Astragalus polysaccharide （APS） against HgN2 avian influenza virus （H9N2 AIV） infection in chickens. The effects of APS treatment on H9N2 infection was evaluated by an Mqq- [3（4, 5-dimethylthiazol-2-yl）-2, 3-diphenyl tetrazolium bromide] assay and analysis of MFIC and cytokine mRNA expression. The effect on lymphocyte and serum antibody titers in vivo was also investigated. IL-4, IL-6, IL-10, LITAF, IL-12 and antibody titers to H9N2 AIV wet enhanced in the first week after APS treatment. The results indicated that APS treatment reduces H9N2 AIV replication and promotes early humoral immune responses in young chickens.This study investigated the humoral immunization of Astragalus polysaccharide （APS） against HgN2 avian influenza virus （H9N2 AIV） infection in chickens. The effects of APS treatment on HgN2 infection was evaluated by an M]q- [3（4, 5-dimethylthiazol-2-yl）-2, 3-diphenyl tetrazolium bromide] assay and analysis of MHC and cytokine mRNA expression. The effect on lymphocyte and serum antibody titers in vivo was also investigated. IL-4, IL-6, IL-10, LITAF, IL-12 and antibody titers to PIgN2 AIV were enhanced in the first week after APS treatment. The results indicated that APS treatment reduces HgN2 AIV replication and promotes early humoral immune responses in young chickens.
基金supported by the National Natural Science Foundation of China(Nos.30771501 and 81102850)the National Basic Research Program(973)of China(No.2011CB811302)+2 种基金the National Mega Project on Major Drug Development(No.2009ZX09301-014-1)the Chinese 111 Project(No.B06018)the Wuhan Municipal Project(No.201160923296),China
文摘Objective： To evaluate the potential adjuvant effect of Agrocybe aegerita lectin （AAL）, which was isolatedfrom mushroom, against a virulent H9N2 strain in vivo and in vitro. Methods： In trial 1, 50 BALB/c male mice （8 weeksold） were divided into five groups （n=10 each group） which received a subcutaneous injection of inactivated HgN2（control）, inactivated HgN2＋0.2% （w/w） alum, inactivated HgN2＋0.5 mg recombinant AAL/kg body weight （BW）, inac-tivated HgN2＋1.0 mg AAl_/kg BW, and inactivated H9N2＋2.5 mg AAL/kg BW, respectively, four times at 7-d intervals. Intrial 2, 30 BALB/c male mice （8 weeks old） were divided into three groups （n=10 each group） which received a sub-cutaneous injection of inactivated HgN2 （control）, inactivated HmN2＋2.5 mg recombinant wild-type AAL （AAL-wt）/kg BWand inactivated H9N2＋2.5 mg carbohydrate recognition domain （CRD） mutant AAL （AAL-mutR63H）/kg BW,respectively, four times at 7-d intervals. Seven days after the final immunization, serum samples were collectedfrom each group for analysis. Hemagglutination assay, immunogold electron microscope, lectin blotting, and co-immunoprecipitation were used to study the interaction between hAL and HgN2 in vitro. Results： IgG, IgG1, and IgG2aantibody levels were significantly increased in the sera of mice co-immunized with inactivated HgN2 and AAL whencompared to mice immunized with inactivated H^N2 alone. No significant increase of the IgG antibody level was de-tected in the sera of the mice co-immunized with inactivated HgN2 and AAL-mutR63H. Moreover, AAL-wt, but notmutant AAL-mutR63H, adhered to the surface of H9N2 virus. The interaction between AAL and the H9N2 virus wasfurther demonstrated to be associated with the CRD of AAL binding to the surface glycosylated proteins, hemagglutininand neuraminidase. Conclusions： Our findings indicated that AAL could be a safe and effective adjuvant capable ofboosting humoral immunity against HgN2 viruses in mice through its interaction with the viral surface glycosylatedproteins, hemagglutinin and neuraminidase.
